

Daniel Coriu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5865891/publications.pdf>

Version: 2024-02-01

34
papers

441
citations

840776
11
h-index

752698
20
g-index

35
all docs

35
docs citations

35
times ranked

696
citing authors

#	ARTICLE	IF	CITATIONS
1	TNF-alpha releasing capacity of the whole blood drops after open total splenectomy, but increases after partial/subtotal or minimally invasive splenectomy. <i>Acta Chirurgica Belgica</i> , 2022, 122, 346-356.	0.4	1
2	Controversial Flow Cytometry Monitoring of a Relapse Case of Pediatric T Cell Acute Lymphoblastic Leukemia: A Case Report. <i>Frontiers in Medicine</i> , 2022, 9, 858809.	2.6	0
3	The Difficult-to-Treat del 17 p Patientâ€™A Case Report in Chronic Lymphocytic Leukemia. <i>Medicina (Lithuania)</i> , 2022, 58, 33.	2.0	1
4	Editorial: Modern Approaches to Hemophilia Management: Gene Therapy and Beyond. <i>Frontiers in Medicine</i> , 2022, 9, 859710.	2.6	0
5	Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. <i>ESC Heart Failure</i> , 2021, 8, 2380-2396.	3.1	29
6	Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study. <i>Frontiers in Medicine</i> , 2021, 8, 686165.	2.6	21
7	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 3940.	2.4	10
8	L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 4419.	2.4	9
9	Outcomes of patients with Down syndrome and acute leukemia. <i>Medicine (United States)</i> , 2021, 100, e27459.	1.0	8
10	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
11	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	3.5	48
12	Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 833-844.	1.2	38
13	Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphomaâ€™Romanian Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 2417.	2.4	12
14	Successful treatment of pulmonary haemorrhage and acute respiratory distress syndrome caused by fulminant <i>Stenotrophomonas maltophilia</i> respiratory infection in a patient with acute lymphoblastic leukaemia â€“ case report. <i>BMC Infectious Diseases</i> , 2020, 20, 658.	2.9	5
15	SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?. <i>Frontiers in Oncology</i> , 2020, 10, 1024.	2.8	3
16	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	4.1	11
17	Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 34.	2.7	13
18	Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 484.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	1.3	3
20	Relevance of newly acquired mutations to the prognosis of patients with relapsed multiple myeloma. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 473-475.	0.4	0
21	Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 31-32.	3.0	2
22	SP115RENAL SURVIVAL PROGNOSTIC FACTORS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	1
23	LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. <i>Frontiers in Oncology</i> , 2019, 9, 892.	2.8	20
24	Letâ€™s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2019, 10, 2856.	4.8	8
25	Hypercoagulability and Vascular Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 237-245.	2.2	20
26	Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. <i>Blood</i> , 2018, 132, 2695-2699.	1.4	4
27	Real-world multiple myeloma management practice patterns and outcomes in six Central and Eastern European countries. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 500-511.	0.4	10
28	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	2.5	29
29	Thrombophilia genetic testing in Romanian young women with acute thrombotic events: role of Factor V Leiden, Prothrombin G20210A, MTHFR C677T and A1298C polymorphisms / Evaluarea genetică a trombofiliei la femei tinere din România cu evenimente acute trombotice: rolul Factorului V Leiden, Protrombinei G20210A, polimorfismelor MTHFR C677T și A1298C. <i>Romanian Journal of Laboratory Medicine</i> , 2016, 24, 291-305.	0.2	3
30	A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing. <i>Romanian Journal of Laboratory Medicine</i> , 2014, 22, .	0.2	4
31	Atherothrombosis in 2 Vascular Territories in a Young Woman: Importance of Thrombophilia Testing. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 108-113.	1.7	4
32	Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I. <i>Arthritis and Rheumatism</i> , 2006, 54, 3545-3550.	6.7	48
33	A molecular basis for nonsecretory myeloma. <i>Blood</i> , 2004, 104, 829-831.	1.4	31
34	Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 215-223.	3.0	33